Patient-reported quality of life after tisagenlecleucel infusion in children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia: a global, single-arm, phase 2 trialTheodore W. Laetsch, Andrew C. Harris, Michael A. Pulsipher et al.|The Lancet Oncology|2019Cited by 90
Patient-reported quality of life (QOL) following CTL019 in pediatric and young adult patients (pts) with relapsed/refractory (r/r) b-cell acute lymphoblastic leukemia (B-ALL).Andrew C. Dietz, Andrew C. Harris, Stephan A. Grupp et al.|Journal of Clinical Oncology|2017Cited by 2